NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer-Reference-Cited by-同舟云学术

NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer

Published:2022-10 Issue:14 Volume:16 Page:1029-1041
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Konrad Sarah M¹²,Schwamborn Kristina³,Krüger Achim⁴,Honert Katja⁴,Schmitt Manfred¹,Hellmann Daniela¹,Schmalfeldt Barbara¹⁵,Meindl Alfons¹⁶,Kiechle Marion¹,Quante Anne S¹⁷,Brambs Christine⁸,Grill Sabine¹,Ramser Juliane¹

Affiliation:

1. Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany

2. German Cancer Consortium (DKTK), partner site München, & German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany

3. Institute of Pathology, School of Medicine, Technical University of Munich, Munich, 81675, Germany

4. Institute of Experimental Oncology & Therapy Research, School of Medicine, Technical University of Munich, Munich, 81675, Germany

5. Department of Gynecology & Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany

6. Department of Gynecology & Obstetrics, University Hospital Munich, Ludwig-Maximilians-Universität München, Munich, 81377, Germany

7. Institute of Human Genetics, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, 79106, Germany

8. Department of Gynecology & Obstetrics, Cantonal Hospital of Lucerne, Lucerne, 6000, Switzerland

Abstract

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.

Funder

German Cancer Consortium (DKTK)

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2021-0781

Reference32 articles.

1. Cancer Statistics, 2021

2. Carcinoma of the Ovary

3. Ovarian cancer statistics, 2018

4. Zentrum Für Krebsregisterdaten und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2015/2016. 12 Robert Koch-Institute, Berlin (2019).

5. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)